Sign in Subscribe
Securities law

Lexaria Bioscience Corp. Files Form 8-K: Entry into a Material Definitive Agreement

Strategic Insights

— 1 min read

Lexaria Bioscience Corp., a Nevada-based company, has filed a Form 8-K with the U.S. Securities and Exchange Commission on June 12, 2025, announcing the entry into a Change Order with Novotech (Australia) Pty Limited. This Change Order amends the terms of the Project Agreement (PA) between Lexaria Bioscience Corp. and Novotech, adding a fifth study arm to an ongoing clinical study investigating DehydraTECH-tirzepatide capsules. The study aims to explore the efficacy of DehydraTECH-tirzepatide capsules in combination with glucagon-like peptide 1 agonists in pre- and Type II Diabetes. The Change Order also increases the number of subjects from 20 to 24 in the existing study arms and adds 24 more subjects for the new study arm. The total approved budget for this Change Order amounts to approximately AU$1,900,000.

Key Takeaways:

  • Lexaria Bioscience Corp. has filed a Form 8-K with the U.S. Securities and Exchange Commission, announcing a Change Order with Novotech (Australia) Pty Limited.
  • The Change Order adds a fifth study arm to the clinical study "DehydraTECH Cannabidiol alone and in combination with glucagon-like peptide 1 agonists in pre- and Type II Diabetes."
  • The study aims to investigate the efficacy of DehydraTECH-tirzepatide capsules in combination with glucagon-like peptide 1 agonists in pre- and Type II Diabetes.
  • The Change Order increases the number of subjects from 20 to 24 in the existing study arms and adds 24 more subjects for the new study arm.
  • The total approved budget for this Change Order amounts to approximately AU$1,900,000.

Statistics:

  • 5th study arm added to the clinical study "DehydraTECH Cannabidiol alone and in combination with glucagon-like peptide 1 agonists in pre- and Type II Diabetes"
  • Increased budget: AU$1,900,000
  • Number of subjects increased: 24
  • Study aims: Investigate the efficacy of DehydraTECH-tirzepatide capsules in combination with glucagon-like peptide 1 agonists in pre- and Type II Diabetes.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION
  • FORM 8-K CURRENT REPORT (June 12, 2025)
  • LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter)
  • Lexaria Bioscience Corp. (Company)
  • Novotech (Australia) Pty Limited (Partner)

Read more